Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
AssigneeVanderbilt University
InventorsP. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
Life of this patent
Estimating the term…
Abstract
Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
Claims17
A compound of the following formula:
- wherein:
- X1A:
- CH, CR1, or N;
- each R2 is optionally present, independent and chosen from H, D, NH2, CF3, halogen, F, alkyl, Me, or CD3;
- R6 is H, CH3 or CD3;
- R7 is O or —CO—;
- R8 is a bond, alkyl, —NH—, —O—, alkyl-O—;
- R9 is substituted or unsubstituted and chosen from cycloalkyl, tetrahydrofuran, 1,4 dioxane, cyclobutyl, tetrahydropyran;
- and
- n is 0-6;
- or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable derivative thereof.
A pharmaceutical composition comprising a compound having a structure represented by a compound of the following formula:
- wherein:
- X1A:
- CH, CR1, or N;
- each R2 is optionally present, independent and chosen from H, D, NH2, CF3, halogen, F, alkyl, Me, or CD3;
- R6 is H, CH3 or CD3;
- R7 is O or —CO—;
- R8 is a bond, alkyl, —NH—, —O—, alkyl-O—;
- R9 is substituted or unsubstituted and chosen from cycloalkyl, tetrahydrofuran, 1,4 dioxane, cyclobutyl, tetrahydropyran;
- and
- n is 0-6;
- or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
A method for the treatment of a neurotransmission dysfunction and other disease states associated with mGluR4 activity in a mammal comprising the step of administering to the mammal at least one compound in a dosage and amount effective to treat the dysfunction in the mammal, the compound having a structure represented by a compound of the following formula:
- wherein:
- X1A:
- CH, CR1, or N;
- each R2 is optionally present, independent and chosen from H, D, NH2, CF3, halogen, F, alkyl, Me, or CD3;
- R6 is H, CH3 or CD3;
- R7 is O or —CO—;
- R8 is a bond, alkyl, —NH—, —O—, alkyl-O—;
- R9 is substituted or unsubstituted and chosen from cycloalkyl, tetrahydrofuran, 1,4 dioxane, cyclobutyl, tetrahydropyran;
- and
- n is 0-6;
- or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable derivative thereof.
Dependencies are inferred from the claim text.